tiprankstipranks
Rhythm Biosciences Secures $3.5M for Cancer Test Development
Company Announcements

Rhythm Biosciences Secures $3.5M for Cancer Test Development

Rhythm Biosciences Ltd. (AU:RHY) has released an update.

Don't Miss Our Christmas Offers:

Rhythm Biosciences Ltd has successfully raised $3.5 million through a strong share placement, priced at $0.10 per share, to further develop and commercialize its ColoSTAT® Multiplex colorectal cancer test. The placement attracted significant interest from new institutional and sophisticated investors, reflecting confidence in the company’s innovative cancer diagnostics technology. The funds will support the finalization of the test kit, clinical validation, and expansion of their R&D pipeline.

For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App